Biochemical Characterization of PRV-1, a Novel Hematopoietic Cell Surface Receptor, Which is Overexpressed in Polycythemia Rubra Vera
Overview
Affiliations
The cDNA for polycythemia rubra vera 1 (PRV-1), a novel hematopoietic receptor, was recently cloned by virtue of its overexpression in patients with polycythemia vera. PRV-1 is a member of the uPAR/CD59/Ly6 family of cell surface receptors, which share a common cysteine-rich domain and are tethered to the cell surface via a glycosylphosphatidylinositol (GPI) link. We have determined the intron-exon structure of the PRV1 gene and show that the locus is structurally intact in patients with polycythemia vera. Thus, PRV-1 overexpression in these patients is not due to rearrangement or structural alteration of the gene. Northern blot analysis detects multiple PRV-1 transcripts. Here we show that these transcripts arise from alternative polyadenylation and encode the same protein. Biochemical analysis reveals that PRV-1 is N-glycosylated and embedded in the cell membrane by a lipid anchor, like other members of this family. Moreover, PRV-1 is shed from the cell surface because soluble protein can be detected in cell supernatants. Fluorescence-activated cell sorting analysis of stably transfected cells revealed that PRV-1 is recognized by antibodies directed against the neutrophil antigen NB1/CD177. Flow cytometry of bone marrow and peripheral blood of both healthy donors and patients with polycythemia vera showed that PRV-1 protein is expressed on myeloid cells of the granulocytic lineage. However, unlike the significant difference in PRV-1 expression observed on the mRNA level, the amount of PRV-1 protein on the cell surface is not consistently elevated in patients with polycythemia vera compared with healthy controls. Therefore, quantification of PRV-1 surface expression cannot be used for the diagnosis of polycythemia vera.
Dual role of CD177 + neutrophils in inflammatory bowel disease: a review.
Zheng C, Li J, Chen H, Ma X, Si T, Zhu W J Transl Med. 2024; 22(1):813.
PMID: 39223577 PMC: 11370282. DOI: 10.1186/s12967-024-05539-3.
Volkmann J, Schmitz J, Nordlohne J, Dong L, Helmke A, Sen P Clin Exp Immunol. 2019; 199(1):97-108.
PMID: 31509227 PMC: 6904607. DOI: 10.1111/cei.13372.
Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
Vaddi K, Verstovsek S, Kiladjian J Blood Lymphat Cancer. 2019; 6:7-19.
PMID: 31360077 PMC: 6467337. DOI: 10.2147/BLCTT.S101185.
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.
Mascarenhas J, Roper N, Chaurasia P, Hoffman R Clin Epigenetics. 2012; 2(2):197-212.
PMID: 22704337 PMC: 3365400. DOI: 10.1007/s13148-011-0050-6.
Slezak S, Jin P, Caruccio L, Ren J, Bennett M, Zia N J Transl Med. 2009; 7:39.
PMID: 19497108 PMC: 2701925. DOI: 10.1186/1479-5876-7-39.